Kezar Life Sciences

$5.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-1.26%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell KZR and other stocks, options, and ETFs commission-free!

About KZR

Kezar Life Sciences, Inc. Common Stock, also called Kezar Life Sciences, is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA. The listed name for KZR is Kezar Life Sciences, Inc. Common Stock.

CEO
John Fowler
Employees
40
Headquarters
South San Francisco, California
Founded
2015
Market Cap
254.92M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
116.07K
High Today
$5.67
Low Today
$5.34
Open Price
$5.63
Volume
97.64K
52 Week High
$9.79
52 Week Low
$2.18

KZR Earnings

-$0.50
-$0.33
-$0.17
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

VELOU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure